HDAC6 is a therapeutic target in mutant GARS-induced Charcot-Marie-Tooth disease
Veronick Benoy(VIB-KU Leuven Center for Brain & Disease Research), Ludo Van Den Bosch(Allen Institute for Brain Science)
Cited by 120
Related Papers
HDAC6 inhibition reverses axonal transport defects in motor neurons derived from FUS-ALS patients
|Nature Communications|2017|377
Disrupted function and axonal distribution of mutant tyrosyl-tRNA synthetase in dominant intermediate Charcot-Marie-Tooth neuropathy
|Nature Genetics|2006|376
<i>C9orf72</i> -derived arginine-containing dipeptide repeats associate with axonal transport machinery and impede microtubule-based motility
|Science Advances|2021|90
Restoration of histone acetylation ameliorates disease and metabolic abnormalities in a FUS mouse model
|Acta Neuropathologica Communications|2019|89